WO2003092631A3 - Cyclic peptide anti-viral agents and methods - Google Patents

Cyclic peptide anti-viral agents and methods Download PDF

Info

Publication number
WO2003092631A3
WO2003092631A3 PCT/US2003/014372 US0314372W WO03092631A3 WO 2003092631 A3 WO2003092631 A3 WO 2003092631A3 US 0314372 W US0314372 W US 0314372W WO 03092631 A3 WO03092631 A3 WO 03092631A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
viral agents
cyclic peptide
peptide anti
present
Prior art date
Application number
PCT/US2003/014372
Other languages
French (fr)
Other versions
WO2003092631A2 (en
Inventor
M Reza Ghadiri
Original Assignee
Scripps Research Inst
M Reza Ghadiri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, M Reza Ghadiri filed Critical Scripps Research Inst
Priority to AU2003241384A priority Critical patent/AU2003241384A1/en
Publication of WO2003092631A2 publication Critical patent/WO2003092631A2/en
Publication of WO2003092631A3 publication Critical patent/WO2003092631A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a new type of anti-viral agents. Methods of using the present anti-viral agents are also provided.
PCT/US2003/014372 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods WO2003092631A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003241384A AU2003241384A1 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37825602P 2002-05-06 2002-05-06
US60/378,256 2002-05-06

Publications (2)

Publication Number Publication Date
WO2003092631A2 WO2003092631A2 (en) 2003-11-13
WO2003092631A3 true WO2003092631A3 (en) 2005-04-28

Family

ID=29401596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/014372 WO2003092631A2 (en) 2002-05-06 2003-05-06 Cyclic peptide anti-viral agents and methods

Country Status (2)

Country Link
AU (1) AU2003241384A1 (en)
WO (1) WO2003092631A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
WO2010051667A1 (en) * 2008-11-10 2010-05-14 复旦大学 Pharmaceutical compositions comprising cyclic peptide nanotubes and the uses thereof
SG11201500111VA (en) * 2012-08-29 2015-03-30 Agency Science Tech & Res Peptides and uses thereof
WO2014165563A2 (en) * 2013-04-02 2014-10-09 The Scripps Research Institute Uses of cyclic peptides for treating and preventing atherosclerosis
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
RS59119B1 (en) 2014-05-21 2019-09-30 Entrada Therapeutics Inc Cell penetrating peptides and methods of making and using thereof
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
WO2019139126A1 (en) * 2018-01-11 2019-07-18 国立大学法人東京大学 Ntcp inhibitor
EP3749365A4 (en) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
WO2019217682A1 (en) 2018-05-09 2019-11-14 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIN M. ET AL.: "Hantaan virus enters cells by Clathrin-dependent receptor-mediated endocytosis", VIROLOGY, vol. 294, 2002, pages 60 - 69, XP004438115 *
MUTTER M. ET AL.: "Macrocyclization equilibria of polypeptides", J. OF THE AMERICAN CHEMICAL SOCIETY, vol. 99, no. 25, 1977, pages 8307 - 8314, XP002984571 *
ROY A.M. ET AL.: "Early stages of Influenza virus entry into Mv-1 lung cells: involvement of Dynamin", VIROLOGY, vol. 267, 2000, pages 17 - 28, XP004436149 *

Also Published As

Publication number Publication date
AU2003241384A1 (en) 2003-11-17
WO2003092631A2 (en) 2003-11-13
AU2003241384A8 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
AU2003266233A1 (en) Novel tubulysin analogues
AU2003214224A1 (en) Parametric ring emitter
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
WO2003074546A3 (en) Streptavidin-binding peptide
WO2003092631A3 (en) Cyclic peptide anti-viral agents and methods
WO2000063247A3 (en) Osteopontin-derived chemotactic and inhibitory agents and uses therefor
AU2003290563A8 (en) Leptin-related peptides
GB2392510B (en) Ring resonator
WO2004052312A3 (en) Anti-infectives
AU2002226687A1 (en) Benzylamine analogue
AU2003292859A1 (en) Feng-you-jing spray
AU2003234638A8 (en) Luminogenic protease substrates
AU2003225394A1 (en) Necktie wearing-device
AU2003290818A1 (en) Topoisomerase-targeting agents
WO2004016640A3 (en) 5 ANDROSTEN-3β-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
WO2004047751A3 (en) Calcilytic compounds
ITTO20030295A1 (en) CYLINDER GROUP AND HERMETIC COMPRESSOR THAT INCLUDES IT.
AU2003214836A1 (en) Combined gemstone
AU2003218232A1 (en) Peptide analogues and uses thereof
AUPQ599500A0 (en) Novel peptides, modulatory agents therefor and methods of using them
GB0202275D0 (en) Peptide
AU2002256932A1 (en) Hula hoop
AU2003214299A1 (en) Hiv-1 virus tat-protein mutants
AU2003275127A8 (en) P. ariasi polypeptides, p. perniciosus polypeptides and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP